Entry |
|
Name |
Lorecivivint (USAN/INN); Adavivint |
Formula |
C29H24FN7O
|
Exact mass |
505.2026
|
Mol weight |
505.5456
|
Structure |
|
Efficacy |
Anti-inflammatory, Antirheumatic, Wnt signalling pathway inhibitor |
Comment |
Treatment of osteoarthritis
|
Target |
|
Brite |
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
CMGC group
CLK2
D11588 Lorecivivint (USAN/INN)
DYRK1A
D11588 Lorecivivint (USAN/INN)
|
Other DBs |
|
KCF data |
ATOM 38
1 C8y C 19.2500 -13.7200
2 N4x N 19.2500 -15.1200
3 C8y C 20.5815 -15.5526
4 N5x N 21.4044 -14.4200
5 C8y C 20.5815 -13.2874
6 C8x C 20.8726 -11.9180
7 N5x N 19.8322 -10.9812
8 C8x C 18.5007 -11.4138
9 C8y C 18.2096 -12.7832
10 C8y C 16.8617 -13.2209
11 C8x C 15.8306 -12.2921
12 C8x C 14.4990 -12.7245
13 C8x C 14.2077 -14.0939
14 C8y C 15.2388 -15.0226
15 C8x C 16.5703 -14.5902
16 X F 14.9424 -16.4135
17 C8y C 21.0103 -16.8722
18 N5x N 20.1850 -18.0083
19 N4x N 21.0104 -19.1443
20 C8y C 22.3458 -18.7103
21 C8y C 22.3458 -17.3061
22 C8x C 23.5583 -19.4103
23 C8x C 24.7707 -18.7102
24 C8y C 24.7707 -17.3060
25 C8x C 23.5582 -16.6061
26 C8y C 25.9970 -16.5980
27 C8x C 27.1856 -17.2845
28 C8y C 28.3981 -16.5846
29 C8x C 28.3983 -15.1846
30 N5x N 27.2097 -14.4982
31 C8x C 25.9972 -15.1980
32 N1b N 29.6292 -17.2957
33 C5a C 30.8297 -16.6027
34 C1b C 32.0142 -17.2869
35 O5a O 30.8301 -15.1903
36 C1c C 33.2071 -16.5982
37 C1a C 34.3956 -17.2846
38 C1a C 33.2074 -15.1903
BOND 43
1 1 2 1
2 2 3 1
3 3 4 2
4 4 5 1
5 1 5 1
6 5 6 2
7 6 7 1
8 7 8 2
9 8 9 1
10 1 9 2
11 9 10 1
12 10 11 2
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 2
17 10 15 1
18 14 16 1
19 3 17 1
20 17 18 2
21 18 19 1
22 19 20 1
23 20 21 1
24 17 21 1
25 20 22 2
26 22 23 1
27 23 24 2
28 24 25 1
29 21 25 2
30 24 26 1
31 26 27 2
32 27 28 1
33 28 29 2
34 29 30 1
35 30 31 2
36 26 31 1
37 28 32 1
38 32 33 1
39 33 34 1
40 33 35 2
41 34 36 1
42 36 37 1
43 36 38 1
|